Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 10—October 2013

Dispatch

New Clonal Strain of Candida auris, Delhi, India

Anuradha ChowdharyComments to Author , Cheshta Sharma, Shalini Duggal, Kshitij Agarwal, Anupam Prakash, Pradeep Kumar Singh, Sarika Jain, Shallu Kathuria, Harbans S. Randhawa, Ferry Hagen, and Jacques F. Meis
Author affiliations: Author affiliations: Vallabhbhai Patel Chest Institute, Delhi, India (A. Chowdhary, C. Sharma, K. Agarwal, A. Prakash, P.K. Singh, S. Kathuria, H.S. Randhawa); B.L. Kapur Memorial Hospital, New Delhi, India (S. Duggal, S. Jain); Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands (F. Hagen, J.F. Meis); and Radboud University Nijmegen Medical Centre, Nijmegen (J.F. Meis)

Main Article

Table 1

Results of In vitro antifungal susceptibility testing of 12 Candida auris isolates originating from fungemia patients in 2 hospitals, Delhi, India, 2009–2011

MIC, mg/L*
Drug†
AMB
FLU
ITC
VRC
ISA
POS
FC
CAS
MFG
AFG
MIC50 0.25 32 0.125 0.5 0.125 0.125 0.125 0.25 0.06 0.25
MIC90 0.5 64 0.25 1 0.25 0.25 0.125 0.25 0.125 0.5
GM 0.33 28.5 0.15 0.39 0.10 0.12 0.125 0.23 0.072 0.26
Range 0.25–1 16–64 0.125–0.25 0.125–1 <0.015–0.25 0.06–0.25 0.125 0.125–0.25 0.06–0.125 0.125–0.5

*MIC50, 50% minimum inhibitory concentration; MIC90, 90% minimum inhibitory concentration; GM, geometric mean of MICs.
†AMB, amphotericin B; FLU, fluconazole; ITC, itraconazole; VRC, voriconazole; ISA, isavuconazole; POS, posaconazole; FC, flucytosine; CAS, caspofungin; MFG, micafungin; AFG, anidulafungin.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO